Lakefront Biotherapeutics (LKFT) Finished Goods (2020 - 2023)
Lakefront Biotherapeutics (LKFT) posted quarterly Finished Goods of $6.6 million for Q4 2023, down 19.99% year-over-year from $8.2 million in Q4 2022, and down 19.99% quarter-over-quarter from $8.2 million in Q4 2022.
Lakefront Biotherapeutics (LKFT) Finished Goods (2020 - 2023) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Finished Goods for 4 consecutive years, with $6.6 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Finished Goods fell 19.99% year-over-year to $6.6 million; the TTM figure through Dec 2023 stood at $6.6 million (down 19.99% YoY), while the FY2023 annual figure was $6.6 million, down 19.99% from the prior year.
- Finished Goods retreated to $6.6 million in Q4 2023 per LKFT's latest filing, from $8.2 million in the prior quarter.
- Across five years, Finished Goods topped out at $8.2 million in Q4 2022 and bottomed at $42922.4 in Q4 2020.
- Historically, Finished Goods has averaged $5.1 million across 4 years, with a median of $6.1 million in 2023.
- Annual changes were most pronounced in 2021 — Finished Goods jumped 12804.92% — and 2023, when it declined 19.99%.
- Lakefront Biotherapeutics' Finished Goods stood at $42922.4 in 2020, then jumped by 12804.92% to $5.5 million in 2021, then jumped by 48.51% to $8.2 million in 2022, then fell by 19.99% to $6.6 million in 2023.
- Business Quant data shows LKFT's Finished Goods at $6.6 million in Q4 2023, $8.2 million in Q4 2022, and $5.5 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 6.58 Mn |
| Dec 31, 2022 | 8.23 Mn |
| Dec 31, 2021 | 5.54 Mn |
| Dec 31, 2020 | 42,922.43 |